Literature DB >> 16132296

NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis.

N Nasser1, Z Perles2, A J J T Rein2, A Nir3.   

Abstract

Children with myocarditis and dilated cardiomyopathy may recover clinically and echocardiographically. Plasma levels of the N-terminal segment of B-type natriuretic peptide prohormone (NT-proBNP), a sensitive marker for cardiac dysfunction, may reflect residual cardiac damage in these patients. The purpose of this study was to evaluate NT-proBNP status in pediatric patients with a history of myocarditis and dilated cardiomyopathy. Cardiac evaluation was performed and the levels of NT-proBNP were measured in 23 children who had a history of myocarditis or dilated cardiomyopathy. NT-proBNP levels were also measured in 56 age-matched control children. Nine of the 23 patients had evidence of left ventricular dysfunction (DCM group), whereas 14 had none (recovery). NT-proBNP levels were higher in the DCM group (3154 +/- 2858 pg/ml) than in the recovery group (122 +/- 75 pg/ml, p < 0.001) and the control group (113 +/- 96 pg/ml, p < 0.001). There was no difference between the recovery and the control groups (p = 0.45), and none of the recovered patients had a NT-proBNP level higher than the upper limit of normal. The area under the receiver operating characteristics curve for the diagnosis of persistent left ventricular dysfunction was 0.984. NT-proBNP levels correlated with echocardiographically derived shortening fraction and with clinical score. NT-proBNP is a good marker for persistent left ventricular dysfunction in children who have had myocarditis or cardiomyopathy. In this group of patients, NT-proBNP levels are normal in children who recover echocardiographically, suggesting no residual hemodynamic abnormalities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16132296     DOI: 10.1007/s00246-005-1027-z

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  19 in total

1.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.

Authors:  Emily Lubien; Anthony DeMaria; Padma Krishnaswamy; Paul Clopton; Jen Koon; Radmila Kazanegra; Nancy Gardetto; Erin Wanner; Alan S Maisel
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

2.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.

Authors:  A M Richards; R Doughty; M G Nicholls; S MacMahon; N Sharpe; J Murphy; E A Espiner; C Frampton; T G Yandle
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

Review 3.  Natriuretic hormones.

Authors:  E A Espiner; A M Richards; T G Yandle; M G Nicholls
Journal:  Endocrinol Metab Clin North Am       Date:  1995-09       Impact factor: 4.741

4.  Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure.

Authors:  Thomas S Mir; Sönke Marohn; Stephanie Läer; Michele Eiselt; Oswin Grollmus; Jochen Weil
Journal:  Pediatrics       Date:  2002-12       Impact factor: 7.124

5.  The New York University Pediatric Heart Failure Index: a new method of quantifying chronic heart failure severity in children.

Authors:  D Connolly; M Rutkowski; M Auslender; M Artman
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

6.  Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice.

Authors:  Graham McGeoch; John Lainchbury; G Ian Town; Les Toop; Eric Espiner; A Mark Richards
Journal:  Eur J Heart Fail       Date:  2002-08       Impact factor: 15.534

7.  Infantile dilated cardiomyopathy. Relation of outcome to left ventricular mechanics, hemodynamics, and histology at the time of presentation.

Authors:  A Matitiau; A Perez-Atayde; S P Sanders; T Sluysmans; I A Parness; P J Spevak; S D Colan
Journal:  Circulation       Date:  1994-09       Impact factor: 29.690

8.  N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases.

Authors:  A Nir; B Bar-Oz; Z Perles; R Brooks; A Korach; A J J T Rein
Journal:  Acta Paediatr       Date:  2004-05       Impact factor: 2.299

9.  Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure.

Authors:  Serge Masson; Tarcisio Vago; Gabriella Baldi; Monica Salio; Noeleen De Angelis; Enrico Nicolis; Aldo P Maggioni; Roberto Latini; Guido Norbiato; Maurizio Bevilacqua
Journal:  Clin Chem Lab Med       Date:  2002-08       Impact factor: 3.694

Review 10.  Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects.

Authors:  Fiorella Calabrese; Gaetano Thiene
Journal:  Cardiovasc Res       Date:  2003-10-15       Impact factor: 10.787

View more
  7 in total

Review 1.  Plasma B-type natriuretic peptides in children with cardiovascular diseases.

Authors:  Bibhuti B Das
Journal:  Pediatr Cardiol       Date:  2010-10-07       Impact factor: 1.655

Review 2.  Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases.

Authors:  Da-Rong Pu; Jun R Chiong; Qi-chang Zhou
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

Review 3.  Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?

Authors:  Afif El-Khuffash; Eleanor J Molloy
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-07       Impact factor: 5.747

4.  NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.

Authors:  Amal Zidan; Laila M Sherief; Amera El-sheikh; Safaa H Saleh; Doaa A Shahbah; Naglaa M Kamal; Hanan S Sherbiny; Heba Ahmad
Journal:  Dis Markers       Date:  2015-04-16       Impact factor: 3.434

5.  The Use of N-Terminal-Pro-BNP in Preterm Infants.

Authors:  Afif El-Khuffash; Eleanor Molloy
Journal:  Int J Pediatr       Date:  2009-12-30

6.  Comparison between procalcitonin, brain natriuretic peptide, and uric acid in children with cardiomyopathy and controls.

Authors:  Noor Mohammad Noori; Maziar Mahjoubifard; Iraj Shahramian; Alireza Teimouri; Alireza Jahangirifard
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

7.  N-terminal pro-brain natriuretic peptide as a biomarker for predicting coronary artery lesion of Kawasaki disease.

Authors:  Xiaolan Zheng; Yi Zhang; Lei Liu; Peng Yue; Chuan Wang; Kaiyu Zhou; Yimin Hua; Gang Wu; Yifei Li
Journal:  Sci Rep       Date:  2020-03-20       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.